Q2 EPS Forecast for Corcept Therapeutics Lifted by Analyst

Key Points

• HC Wainwright raised its Q2 2026 EPS estimate for Corcept from ($0.07) to $0.02, retains a "Buy" rating with a $75 price target and projects sharply higher EPS through FY2030.
• Corcept recently reported Q1 EPS of ($0.30) and revenue of $164.9M, missing analyst expectations of ($0.11) EPS and $185.8M revenue.
• Several firms have upgraded the stock and lifted targets (e.g., Piper Sandler to $88, Canaccord to $110), leaving a consensus rating of "Moderate Buy" and an average price target of $74.67.

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Stock analysts at HC Wainwright increased their Q2 2026 earnings per share estimates for shares of Corcept Therapeutics in a report issued on Monday, May 4th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of $0.02 for the quarter, up from their prior estimate of ($0.07). HC Wainwright currently has a "Buy" rating and a $75.00 price target on the stock. The consensus estimate for Corcept Therapeutics' current full-year earnings is $0.35 per share. HC Wainwright also issued estimates for Corcept Therapeutics' Q4 2026 earnings at $0.71 EPS, FY2026 earnings at $0.76 EPS, Q1 2027 earnings at $0.44 EPS, Q2 2027 earnings at $0.71 EPS, FY2027 earnings at $2.84 EPS, FY2028 earnings at $3.73 EPS, FY2029 earnings at $5.91 EPS and FY2030 earnings at $8.60 EPS.

CORT has been the subject of several other reports. Wolfe Research raised shares of Corcept Therapeutics from an "underperform" rating to a "peer perform" rating in a research report on Thursday, March 26th. Zacks Research raised shares of Corcept Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Monday. Piper Sandler lifted their price target on shares of Corcept Therapeutics from $73.00 to $88.00 and gave the company an "overweight" rating in a research note on Friday. Truist Financial upgraded Corcept Therapeutics to a "strong-buy" rating in a report on Wednesday, March 25th. Finally, Canaccord Genuity Group increased their price objective on Corcept Therapeutics from $100.00 to $110.00 and gave the stock a "buy" rating in a research note on Thursday, March 26th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $74.67.

Corcept Therapeutics Trading Down 0.5%

NASDAQ CORT opened at $51.37 on Wednesday. The stock has a market cap of $5.51 billion, a PE ratio of 146.76 and a beta of 0.36. Corcept Therapeutics has a 12 month low of $28.66 and a 12 month high of $91.00. The company's 50-day moving average price is $39.47 and its 200-day moving average price is $54.18.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.19). Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The business had revenue of $164.90 million during the quarter, compared to analysts' expectations of $185.83 million. During the same quarter in the previous year, the business earned $0.17 EPS. The business's revenue for the quarter was up 4.9% on a year-over-year basis.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, CEO Joseph K. Belanoff sold 26,198 shares of the firm's stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $50.07, for a total transaction of $1,311,733.86. Following the transaction, the chief executive officer owned 2,918,326 shares of the company's stock, valued at approximately $146,120,582.82. This trade represents a 0.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider William Guyer sold 20,000 shares of the company's stock in a transaction that occurred on Tuesday, April 7th. The stock was sold at an average price of $40.97, for a total transaction of $819,400.00. Following the completion of the sale, the insider directly owned 2,231 shares of the company's stock, valued at $91,404.07. The trade was a 89.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 66,198 shares of company stock valued at $2,851,169. Company insiders own 20.70% of the company's stock.

Institutional Trading of Corcept Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp raised its position in shares of Corcept Therapeutics by 0.5% in the 4th quarter. State Street Corp now owns 2,986,056 shares of the biotechnology company's stock worth $103,915,000 after acquiring an additional 15,656 shares in the last quarter. Geode Capital Management LLC boosted its position in Corcept Therapeutics by 38.0% during the fourth quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company's stock valued at $92,892,000 after purchasing an additional 734,646 shares in the last quarter. Morgan Stanley boosted its position in Corcept Therapeutics by 34.1% during the fourth quarter. Morgan Stanley now owns 1,592,059 shares of the biotechnology company's stock valued at $55,404,000 after purchasing an additional 405,081 shares in the last quarter. AQR Capital Management LLC grew its stake in Corcept Therapeutics by 546.9% in the third quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company's stock valued at $125,264,000 after purchasing an additional 1,274,215 shares during the last quarter. Finally, TD Asset Management Inc grew its stake in Corcept Therapeutics by 4.0% in the fourth quarter. TD Asset Management Inc now owns 994,844 shares of the biotechnology company's stock valued at $34,621,000 after purchasing an additional 38,708 shares during the last quarter. Institutional investors own 93.61% of the company's stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.